Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

NCCN > CML > Flashcards

CML Flashcards

1
Q

Preferred option (until the initiation of TKI therapy) to lower very high white blood cell (WBC) counts

A

Hydroxyurea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Rarely indicated for cytoreduction , except for
high-risk indications (eg, persistent priapism, shortness of breath, transient ischemic attack)

A

Leukapheresis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

The presence of major route additional chromosomal abnormalities (ACAs) in Ph-positive cells may have a negative prognostic impact on survival in patients with accelerated phase

A
  • trisomy 8
  • isochromosome 17q
  • second Ph
  • trisomy 19
  • chromosome 3 abnormalities
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

If treatment is needed during pregnancy, it is preferable to initiate treatment with

A

Interferon alfa-2a

TKI therapy, particularly during the first trimester, should be avoided because of teratogenic risk.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

2G TKIs are preferred:

A
  • Intermediateor high-risk score
  • Younger patients who are interested in ultimately discontinuing treatment
  • Young patients assigned female at birth whose goal is to achieve a deep and rapid molecular response and eventual discontinuation of TKI therapy for family planning purposes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

TKI preferred for older patients with comorbidities such as cardiovascular disease.

A

Imatinib

Nilotinib or bosutinib may be preferred for patients with a history of lung disease or deemed to be at risk of developing pleural effusions.

Dasatinib or bosutinib may be preferred in patients with a history of arrhythmias, cardiovascular disease, pancreatitis, or hyperglycemia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

TRUE OR FALSE

Disease progression to advanced phase while on TKI therapy has worse prognosis than de novo advanced phase CML.

A

TRUE

Disease progression to advanced phase while on TKI therapy has worse prognosis than de novo advanced phase CML.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

TRUE OR FALSE

Lumbar puncture and CNS prophylaxis is recommended for both myeloid and lymphoid BP-CML.

A

FALSE

Lumbar puncture and CNS prophylaxis is recommended for lymphoid BP-CML.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How to differentiate between de novo BP-CML and de novo Ph-positive ALL.

A

Perform interphase FISH for the detection of BCR::ABL1 transcript on blood granulocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Drug indicated for the treatment of AP-CML that is resistant and/or intolerant to two or more TKIs.

A treatment option for patients with disease progression to AP-CML.

A

Omacetaxine

Omacetaxine is NOT a treatment option for patients who present with AP-CML

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Preferred treatment option for patients with a T315I mutation in any phase.

It is also a treatment option for CP-CML with resistance or intolerance to at least two prior TKIs or for patients with AP-CML or BP-CML for whom no other TKI is indicated.

A

Ponatinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Another treatment option for CP-CML patients with the T315I mutation and/or CP-CML with resistance or intolerance to at least two prior TKIs.

A

Asciminib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Preferred over bosutinib in patients with F317L mutation

A

Nilotinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Contraindicated mutations for Asciminib

A

A337T, P465S, or F359V/I/C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Contraindicated mutations for Bosutinib

A

T315I, V299L, G250E, or F317Laa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Contraindicated mutations for Dasatinib

A

T315I/A, F317L/V/I/C, or V299L

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Contraindicated mutations for Nilotinib

A

T315I, Y253H, E255K/V, or F359V/C/I

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

If CCyR post Allogeneic HCT, frequency of qPCR would be

A

Every 3 mo for 2 y, then every 3–6 mo thereafter

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

If persistently negative on qPCR post allo HCT, consider TKIi therapy for at least ____ year in patients with prior AP-CML or BP-CML

A

1 year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Modified MDACC Criteria for AP-CML

A
  • Peripheral blood myeloblasts ≥15% and <30%
  • Peripheral blood myeloblasts and promyelocytes combined ≥30%
  • Peripheral blood basophils ≥20%
  • Platelet count ≤100 x 109/L unrelated to therapy
  • Additional clonal cytogenetic abnormalities in Ph+ cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

IBMTR criteria for BP-CML

A
  • ≥30% blasts in the blood, marrow, or both
  • Extramedullary infiltrates of leukemic cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

TRUE OR FALSE

TKI therapy appears to affect some male hormones at least transiently, but does not appear to have a deleterious effect on male fertility.

A

TRUE

TKI therapy appears to affect some male hormones at least transiently, but does not appear to have a deleterious effect on male fertility.

Miscarriage or fetal abnormality rate is not elevated in female partners of male patients on TKI therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

TRUE OR FALSE

In patients assigned male at birth, TKI therapy must be discontinued if a pregnancy is planned.

A

FALSE

In patients assigned male at birth, TKI therapy need not be discontinued if a pregnancy is planned.

In patients assigned female at birth, TKI therapy should be stopped prior to natural conception, and patients should remain off therapy during pregnancy

But the optimal timing of discontinuation is unknown.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

The panel recommends against the use of hydroxyurea during pregnancy, especially in the ________ trimester.

A

First trimester

Leukapheresis can be used for a rising white blood cell (WBC) count and/ or platelet count, although there are no data that recommend at what levels leukapheresis and/or platelet pheresis should be initiated.

Low-dose aspirin or low-molecular-weight heparin can be considered for patients with thrombocytosis.

25
Q

Recommended qPCR monitoring among pregant

A

Monthly monitoring of CBC with differential and frequent monitoring with qPCR (every 1–3 mo) would be helpful to guide the timing for initiation of TKI therapy.

26
Q

TKI therapy can be restarted after ______

A

After delivery

Patients should be advised not to breastfeed while on TKI therapy, as TKIs pass into human breast milk.

27
Q

CRITERIA FOR RESPONSE

Complete hematologic response (CHR)

A
  • Complete normalization of peripheral blood counts with leukocyte count <10 x 109/L
  • Platelet count <450 x 109/L
  • No immature cells, such as myelocytes, promyelocytes, or blasts in peripheral blood
  • No signs and symptoms of disease with resolution of palpable splenomegaly
28
Q

CRITERIA FOR RESPONSE

Cytogenetic response

A
  • Complete cytogenetic response (CCyR): No Ph-positive metaphases
  • Major cytogenetic response (MCyR): 0%–35% Ph-positive metaphases
  • Partial cytogenetic response (PCyR): 1%–35% Ph-positive metaphases
  • Minor cytogenetic response: >35%–65% Ph-positive metaphases
29
Q

CRITERIA FOR RESPONSE

Molecular response

A
  • Early molecular response (EMR): BCR::ABL1 (IS) ≤10% at 3 and 6 months
  • Major molecular response (MMR): BCR::ABL1 (IS) ≤0.1% or ≥3-log reduction in BCR::ABL1 transcripts from the standardized baseline, if qPCR (IS) is not available
  • Deep molecular response (DMR): MR4.0: BCR::ABL1 (IS) ≤0.01% or MR4.5: BCR::ABL1 (IS) ≤0.0032%
30
Q

CRITERIA FOR RESPONSE

Relapse

A
  • Any sign of loss of hematologic response
  • Any sign of loss of CCyR or its molecular response orrelate (MR2.0: BCR::ABL1 [IS] ≤1%) – defined as an increase in BCR::ABL1 transcript to >1%
  • 1-log increase in BCR::ABL1 transcript levels with loss of MMR

The loss of MMR in the presence of a CCyR does not necessarily indicate inadequate response to treatment.

31
Q

MONITORING RESPONSE TO TKI THERAPY

Bone marrow cytogenetics

A
  • At diagnosis
  • Response milestones not reached
  • Any sign of loss of hematologic response
  • Any sign of loss of CCyR or its molecular response correlate (MR2.0: BCR::ABL1 [IS] ≤1%) – defined as an increase in BCR::ABL1 transcript to >1%
32
Q

MONITORING RESPONSE TO TKI THERAPY

qPCR using IS

A
  • At diagnosis
  • Every 3 months after initiating treatment. After BCR::ABL1 (IS) ≤1% (MR2.0)2 has been achieved, every 3 months for 2 years and every 3–6 months thereafter
  • If there is a 1-log increase in BCR::ABL1 transcript levels with MMR, qPCR should be repeated in 1–3 months
33
Q

When to perform BCR::ABL1 kinase domain mutation analysis

A
  • CP-CML
  • Response milestones not reached
  • Disease progression to AP-CML or BP-CML3
34
Q

Criteria for TKI Discontinuation

A
  • Age ≥18 years.
  • CP-CML. No prior history of AP-CML or BP-CML.
  • On approved TKI therapy for at least 3 years.
  • Prior evidence of quantifiable BCR::ABL1 transcript.
  • Stable molecular response (MR4; BCR::ABL1 ≤0.01% IS) for ≥2 years, as documented on at least 4 tests, performed at least 3 months apart.
  • Access to a reliable qPCR test with a sensitivity of detection of at least MR4.5 (BCR::ABL1 ≤0.0032% IS) and that provides results within 2 weeks.
  • Molecular monitoring every 1–2 months for the first 6 months following discontinuation, bimonthly during months 7–12, and quarterly thereafter (indefinitely) for patients who remain in MMR (MR3; BCR::ABL1 ≤0.1% IS).
  • Prompt resumption of TKI within 4 weeks of a loss of MMR with monthly molecular monitoring until MMR is re-established, then every 3 months thereafter is recommended indefinitely for patients who have reinitiated TKI therapy after a loss of MMR. If MMR is not achieved after
    3 months of TKI resumption, BCR::ABL1 kinase domain mutation testing should be performed, and monthly molecular monitoring should be continued for another 6 months.
35
Q

TKIs with studies for TFR

A

Dasatinib, imatinib, or nilotinib

36
Q

Dosing of Asciminib

CP-CML (previously treated with ≥2 TKIs):

CP-CML with T315I mutation:

A

CP-CML (previously treated with ≥2 TKIs): 80 mg orally once daily or 40 mg twice daily

CP-CML with T315I mutation:200 mg orally twice daily

37
Q

Dosing of Bosutinib

Newly diagnosed CP-CML:

CP-CML, AP-CML, or BP-CML with resistance or intolerance to prior therapy:

A

Newly diagnosed CP-CML: 400 mg once daily

CP-CML, AP-CML, or BP-CML with resistance or intolerance to prior therapy: 500 mg once daily

Doses <300 mg/day have not been evaluated.

In patients with pre-existing mild, moderate, and severe hepatic impairment, the recommended dose of bosutinib is 200 mg daily.

38
Q

Dosing of Dasatinib

CP-CML:

AP-CML and BP-CML:

A

CP-CML: 100 mg once daily

AP-CML and BP-CML: 140 mg once daily

39
Q

Rare But Serious Toxicity with Dasatinib

A

Pulmonary arterial hypertension (PAH)

Also associated with reversible inhibition of platelet aggregation that may contribute to bleeding

40
Q

Dosing of Imatinib

CP-CML:

AP-CML and BP-CML:

A

CP-CML: 400 mg once daily

AP-CML and BP-CML: 600 mg once daily

  • Patients with moderate renal impairment (creatinine clearance [CrCl] = 20–39 mL/min) should receive a 50% decrease in the recommended starting dose and future doses can be increased as tolerated.
  • Doses >600 mg are not recommended in patients with mild renal impairment (CrCl = 40–59 mL/min)
41
Q

Side effect of Imatinib that is a major factor reducing quality of life

A

Chronic fatigue (often correlated with musculoskeletal pain and muscular cramps)

Other side effects: Skin hypopigmentation

42
Q

Cardiac toxicity/ black box warning with use Nilotinib

A

Prolongs the QT interval

  • Prior to administration of nilotinib and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies.
  • Electrocardiograms (ECGs) should be obtained to monitor the QT interval at baseline, 7 days after initiation, and periodically thereafter, as well as following any dose adjustments.
43
Q

Dosing of Nilotinib

Newly diagnosed CP-CML:

Resistant or intolerant CP-CML and AP-CML:

BP-CML:

A

Newly diagnosed CP-CML: 300 mg twice daily

Resistant or intolerant CP-CML and AP-CML: 400 mg twice daily

BP-CML: 400 mg twice daily

44
Q

Rare But Serious Toxicity with Nilotinib

A

Peripheral arterial occlusive disease (PAOD)

45
Q

Dosing of Omacetaxine
Resistant or intolerant CP-CML and AP-CML:

Induction dose:

Maintenance dose:

A

Induction dose: 1.25 mg/m2 twice daily for 14 consecutive days of a 28-day cycle

Maintenance dose: 1.25 mg/m2 twice daily for 7 consecutive days of a 28-day cycle

46
Q

Dosing of Ponatinib

CP-CML:

AP-CML and BP-CML:

A

CP-CML: 45 mg once daily with a reduction to 15 mg once daily upon achievement of BCR::ABL1 (IS) ≤1%.

AP-CML and BP-CML: 45 mg once daily

47
Q

Toxicities with Ponatinib:

A
  • Arterial occlusive events (AOEs; including fatal myocardial infarction and stroke) and venous thromboembolic events (VTEs)
  • Heart failure
  • Hepatotoxicity
  • Grade ≥3 skin rash and pancreatitis

Rare But Serious Toxicities
* Hemorrhage
* Cardiac arrhythmias
* Tumor lysis syndrome

Consider use of low-dose aspirin if there is no contraindication

48
Q

BCR::ABL1 transcripts

A
  • e13a2 and e14a2: p210: M-BCR- CML
  • e1a2: p190: m-BCR- Ph+ ALL
  • e19a2: p230: μ-BCR- enhanced neutrophil differentiation

  • e13a2 was more frequent in males and the proportion decreased with age in both sexes
  • e14a2 at baseline was associated with higher molecular response rates to imatinib
  • e1a2 associated with higher risk of disease progression and inferior cytogenetic and molecular responses to TKI therapy
  • e19a2 associated with lower rates of cytogenetic and molecular response to TKIs and inferior survival outcomes
49
Q

Most common clonal cytogenetic evolution in Ph-negative cells on patients treated with TKI therapy

A

Trisomy 8 and loss of Y chromosome

50
Q

Prognostic score based on the patient’s age, spleen size on clinical examination, platelet count, and percentage of blasts in the peripheral blood.

A

Sokal score

51
Q

Prognostic score that includes eosinophils and basophils in the peripheral blood in addition to the same clinical variables used in the Sokal score.

A

Euro score

52
Q

Prognostic score that is based on the same variables as the Sokol score and provides the most useful predictor of CML-related death in patients treated with first-line imatinib.

Focused on CML-specific overall survival (OS).

This is important, as many patients with CML die from non-CML causes, reflecting the efficacy of TKI therapy.

A

European Treatment and Outcome Study long-term survival (ELTS) score

53
Q

The only tool capable of monitoring responses after the patient has achieved CCyR, since BCR::ABL1 transcripts typically remain detectable after CCyR is achieved.

A

qPCR

A major advantage of qPCR is the strong correlation between the results obtained from the peripheral blood and the bone marrow, allowing for molecular monitoring without bone marrow aspirations.

54
Q

The most important goals of TKI therapy are:

A
  • To prevent disease progression to AP-CML or BP-CML
  • To achieve either MR2.0 (≤1% BCR::ABL1 IS, which corresponds to CCyR) or MMR (≤0.1% BCR::ABL1 IS) within 12 months after first-line TKI therapy
55
Q

Clinical trial on Ponatinib that evaluated the safety and efficacy of response-adjusted dosing regimen

Patients were randomized to ponatinib starting doses of 45 mg, 30 mg, and 15 mg, with dose reduction to 15 mg with achievement of ≤1% BCR::ABL1 (IS) in the 45 mg and 30 mg cohorts.

A

OPTIC trial

the FDA has approved a response-adjusted dosing regimen for ponatinib [starting dose of 45 mg once daily with a reduction to 15 mg upon achievement of BCR::ABL1 (IS) ≤1%] for patients with CP-CML with resistance or intolerance to at least two prior kinase inhibitors.

56
Q

TKI with literature supporting Initiation at Lower Dose

A
  • Bosutinib
  • Dasatinib
57
Q

This is an ongoing study that is evaluating the progressing de-escalation of all TKIs after achieving a stable DMR.

Dasatinib or nilotinib

A

OPTkIMA

The DESTINY trial showed the feasibility de-escalation of TKI (imatinib, dasatinib or nilotinib) to half the standard dose for 12 months (imatinib 200 mg once daily; dasatinib 50 mg once daily, or nilotinib 200 mg twice daily) in patients achieving MMR or MR4 followed by discontinuation for 24 months (with frequent monitoring).

NILO-RED study (published only an abstract) demonstrated the feasibility of maintenance therapy with reduced dose nilotinib (once daily) in patients achieving MMR on standard-dose nilotinib (twice daily).

58
Q

TKIs that are currently approved for treatment of CML in children

A

Imatinib, dasatinib, and nilotinib

NCCN (11 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions